Equities Analysts Set Expectations for NRXP FY2024 Earnings

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Stock analysts at HC Wainwright boosted their FY2024 EPS estimates for shares of NRx Pharmaceuticals in a research note issued on Monday, November 25th. HC Wainwright analyst V. Bernardino now forecasts that the company will post earnings per share of ($1.75) for the year, up from their prior estimate of ($3.25). HC Wainwright has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($3.25) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q4 2024 earnings at ($0.20) EPS and FY2025 earnings at ($0.08) EPS.

A number of other research analysts have also weighed in on NRXP. EF Hutton Acquisition Co. I upgraded NRx Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 21st. Ascendiant Capital Markets upped their price objective on shares of NRx Pharmaceuticals from $43.00 to $44.00 and gave the company a “buy” rating in a research note on Thursday, September 12th.

NRx Pharmaceuticals Price Performance

NASDAQ NRXP opened at $1.27 on Wednesday. NRx Pharmaceuticals has a 1-year low of $1.10 and a 1-year high of $7.33. The company has a market cap of $15.35 million, a PE ratio of -0.59 and a beta of 1.27. The stock’s 50 day simple moving average is $1.39 and its 200-day simple moving average is $2.15.

Hedge Funds Weigh In On NRx Pharmaceuticals

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Townsquare Capital LLC purchased a new stake in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 15,041 shares of the company’s stock, valued at approximately $25,000. Townsquare Capital LLC owned about 0.14% of NRx Pharmaceuticals at the end of the most recent quarter. 4.27% of the stock is owned by institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.